say whether the comprehensive workup, including DNA sequencing, blood and stool analysis, and FitBit tracking, made people healthier.
MONEY IN, MONEY OUT
—Bicoastal venture firm Clarus announced a new $910 million fund, its fourth. The fund will focus on later-stage products already in clinical study and on what it called “structured financing” deals.
—The venture arms of international drug giants Novartis (NYSE: [[ticker:NVS]]) and Sanofi (NYSE: [[ticker:SNY]]) co-led a $14 million Series A investment in NeuroVia, of Cambridge, MA, which has a drug to treat the rare metabolic disorder cerebral adrenoleukodystrophy.
—New Haven, CT-based Trevi Therapeutics raised a $50.5 million Series C round of financing as it prepares Phase 3 tests of its anti-itching drug.
—Kala Pharmaceuticals (NASDAQ: [[ticker:KALA]]) of Waltham, MA, raised $90 million in an IPO, selling 6 million shares at $15 apiece. The maker of eye treatments plans to ask the FDA by year’s end to review its lead drug for approval.
—Too late for last week’s roundup: Akcea Therapeutics (NASDAQ: [[ticker:AKCA]]) raised $125 million in its IPO, but the Cambridge biotech had to price its shares well below the planned range.
Image of U.S. map by Dave Winer via a Creative Commons 2.0 license.
